Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study

PURPOSE: Glucarpidase (Voraxaze) is used to treat methotrexate (Mtx) toxicity in patients with delayed Mtx clearance due to impaired renal function. We examine hospital length of stay (LOS), mortality, and readmission rates for Medicare cancer patients with delayed clearance of Mtx treated with gluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Demiralp, Berna, Koenig, Lane, Kala, Jaya, Feng, Chaoling, Hamlett, Elizabeth G, Steele-Adjognon, Marie, Ward, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370073/
https://www.ncbi.nlm.nih.gov/pubmed/30799942
http://dx.doi.org/10.2147/CEOR.S188786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370073/
https://www.ncbi.nlm.nih.gov/pubmed/30799942
http://dx.doi.org/10.2147/CEOR.S188786

Ejemplares similares